



**Date: 25 August 2025**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: PRESS RELEASE**

Dear Sir/Madam,

Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached a Press Release intended for public dissemination.

Thanking you.

Yours faithfully,

**Eris Lifesciences Limited**

---

**Milind Talegaonkar**  
**Company Secretary and Compliance Officer**

**Encl: a/a**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

## Eris Lifesciences Receives ANVISA approval at its Ahmedabad campus

**Mumbai, August 25, 2025:** Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, today announced that a manufacturing unit in its Ahmedabad campus has received approval from ANVISA, which is Brazil's national health regulatory agency. This approval follows a successful inspection conducted by the agency in May 2025 and enables Eris to enter Brazil, the largest pharmaceutical market in South America. A company spokesperson said that this approval by a stringent regulatory authority like Anvisa is a tangible endorsement of the GMP and quality systems at the Company's manufacturing facilities. The said manufacturing facility has been successfully inspected by various other regulatory agencies earlier in the year.

### About Eris Lifesciences Ltd (BSE: 540596, NSE: ERIS):

Established in 2007, Eris is the youngest among the Top-20 pharma companies in India. With an annual branded formulations revenue of INR 3,000+ crore as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women's Health, Oncology and Critical Care. Eris manufactures a wide range of prescription products across several dosage forms including oral solids, oral liquids, softgels, ointments, sprays & gels, sterile injectables and biologics in its 6 manufacturing facilities, and markets these products across India through a network of ~5,000 stockists and 5,00,000+ retail pharmacies.

Eris' revenue and operating profit have grown 2.6x in the last 5 years, with FY 25 revenue of INR 2,894 cr. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of ~ INR 4,000 crore over the last 3 years.

### For further details please contact

Company
Eris Lifesciences Limited CIN No: L24232GJ2007PLC049867
Kruti Raval Email Id: <a href="mailto:kruti@erislifesciences.com">kruti@erislifesciences.com</a>

### Safe Harbor

This document includes forward-looking information and statements including statements concerning the outlook for our businesses. These statements are based on current expectations, estimates and projections that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, allocations of funds by the Governments in the healthcare sector, increasing competition and the conditions of our customers, suppliers and the pharmaceutical industry, global and Indian demand-supply conditions finished goods prices, cyclical demand and pricing in the company's principal markets, changes in government laws and regulations, tax regimes, our provisioning policies, economic and political developments within India and the countries within which the company conducts businesses and other factors such as litigation and labour negotiations.

Any forward-looking statement or information contained in this document speaks only as of the date of the statement.

The company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events or otherwise unless it is required by Law.